Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street ...

For the first time in over 10,000 years, dire wolves are alive again—thanks to genetic engineering by Colossal Biosciences.